Drug Profile
Sargramostim biosimilar - BioSavita
Alternative Names: GM-CSF biosimilar; Leukine™ biosimilarLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator BioSavita
- Class Granulocyte-macrophage colony-stimulating factors
- Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Macrophage stimulants; Neutrophil stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Neutropenia in USA (Parenteral)
- 06 May 2013 Research programme - sargramostim biosimilar - BioSavita is available for licensing as of 06 May 2013. http://biosavita.com/
- 02 May 2013 Early research in Neutropenia in USA (Parenteral)